Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives
|ClinicalTrials.gov Identifier: NCT01089270|
Recruitment Status : Unknown
Verified March 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Not yet recruiting
First Posted : March 18, 2010
Last Update Posted : March 18, 2010
Parkinson Disease is one of the most common neurodegenerative illnesses. First degree relatives of Parkinson patient are in high risk for developing the disease. We will try to detect early changes in brain metabolism before the appearance of Parkinson symptoms.
Participants: first degree relatives of diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes.
The examination results will be given to the participants by a doctor from the neurology department.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Study Start Date :||March 2010|
|Estimated Primary Completion Date :||March 2011|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01089270
|Contact: Einat Even-sapir, PhD, MD||972-3-6974444 ext firstname.lastname@example.org|
|Contact: Ayelet Kurzband, BA||972-3-6974444 ext email@example.com|
|Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center||Not yet recruiting|
|Tel Aviv, Israel|
|Contact: Einat Even-Sapir, MD, PhD 972-3-6974444 ext 3536 Evensap@tasmc.health.gov.il|
|Contact: Ayelet Kurzband, BA 972-3-6974444 ext 3536 firstname.lastname@example.org|
|Sub-Investigator: Hedva Lerman, MD|
|Sub-Investigator: Nir Giladi, PhD, MD|
|Sub-Investigator: Anat Milerman|
|Principal Investigator:||Einat Even-Sapir, MD, PhD||Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|